Fecal Microbiota Transplantation (FMT) for Clostridium Difficile

Conditions

Clostridium Difficile Infection

Brief summary

Faecal microbiota transplantation (FMT) is used for recurrent Clostridium difficile infection (rCDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at Aarhus University Hospital (CEFTA).

Detailed description

Patients are assessed, treated and monitored at Aarhus University Hospital (AUH) as an Integrated part of the project.

Paaske SE, Baunwall SMD, Rubak T, Rågård N, Kelsen J, Hansen MM, Lødrup AB, Erikstrup LT, Mikkelsen S, Erikstrup C, Dahlerup JF, Hvas CL.

2025-06-192 citations

10.1016/j.eclinm.2025.103302

Real-world Effectiveness of Fecal Microbiota Transplantation for First or Second Clostridioides difficile Infection.

Paaske SE, Baumwall SMD, Rubak T, Birn FH, Rågård N, Kelsen J, Hansen MM, Svenningsen L, Krarup AL, Fernis CMC, Neumann A, Lødrup AB, Glerup H, Vinter-Jensen L, Helms M, Erikstrup LT, Grosen AK, Mikkelsen S, Erikstrup C, Dahlerup JF, Hvas CL.

2024-06-118 citations

10.1016/j.cgh.2024.05.038

Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection: A prospective cohort study

Simon Mark Dahl Baunwall, Mette Mejlby Hansen, Sara Ellegaard Andreasen, Marcel Kjærsgaard Eriksen, Nina Rågård et al. (11 authors)

Alimentary Pharmacology & Therapeutics2023-07-2214 citations

10.1111/apt.17642

Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms.

Baek OD, Hjermitslev CK, Dyreborg L, Baunwall SMD, Høyer KL, Rågård N, Hammeken LH, Povlsen JV, Ehlers LH, Hvas CL.

2023-04-165 citations

10.1007/s40121-023-00797-y

Interventions

OTHERFaecal microbiota transplantation (FMT)

FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

No

Inclusion criteria

* age 18 or higher * documented recurrence of Clostridium difficile

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Resolution of Clostridium difficile-Associated disease (CDAD)	8 weeks	Number of patients with resolution of CDAD, , defined by the absense of diarrhea (3 or fewer bowel movements per day) and formed stools (Bristol 5 or lower) or, in the case of abnormal stool frequency or consistency, a negative Clostridium difficile toxin test week 8

Secondary

Measure	Time frame	Description
Clinical effect week 8	8 weeks	Number of patients with clinical effect, defined by absense of diarrhea (3 or fewer bowel movements per day) and formed stools (Bristol 5 or lower)
Negative CD test week 8	8 weeks	Number of patients with negative Clostridium difficile toxin test week 8

Countries

Denmark

Contacts

Primary ContactChristian L Hvas, MD PhD

christian.hvas@auh.rm.dk+4528351839

Outcome results

None listed